Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude sur le pembrolizumab avec le trastuzumab et la chimiothérapie chez des personnes atteintes d'un cancer œsophagogastrique

12 octobre 2026 mis à jour par: Memorial Sloan Kettering Cancer Center

Une étude de phase 2 multicentrique à un seul bras sur le pembrolizumab néoadjuvant avec le trastuzumab et la chimiothérapie dans les tumeurs œsophagogastriques HER2+ résécables

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

Aperçu de l'étude

Description détaillée

Eligible patients will receive 8 peri-operative cycles of pembrolizumab and trastuzumab with chemotherapy (fluoropyrimidine/oxaliplatin doublet for patients initially enrolled and subsequently FLOT [5-fluorouracil, oxaliplatin and docetaxel] followed by pembrolizumab and trastuzumab maintenance to complete 1 total year of therapy.

Type d'étude

Interventionnel

Inscription (Estimé)

49

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Yelena Janjigian, MD
  • Numéro de téléphone: 646-888-4186
  • E-mail: janjigiy@mskcc.org

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02114
        • Recrutement
        • Massachusetts General Hospital (Data Collection Only)
        • Contact:
          • Samuel Klempner, MD
          • Numéro de téléphone: 617-724-4000
    • New Jersey
      • Basking Ridge, New Jersey, États-Unis, 07920
        • Recrutement
        • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
        • Contact:
          • Yelena Janjigian, MD
          • Numéro de téléphone: 646-888-4186
      • Middletown, New Jersey, États-Unis, 07748
        • Recrutement
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • Contact:
          • Yelena Janjigian, MD
          • Numéro de téléphone: 646-888-4186
      • Montvale, New Jersey, États-Unis, 07645
        • Recrutement
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • Contact:
          • Yelena Janjigian, MD
          • Numéro de téléphone: 646-888-4186
    • New York
      • Commack, New York, États-Unis, 11725
        • Recrutement
        • Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
        • Contact:
          • Yelena Janjigian, MD
          • Numéro de téléphone: 646-888-4186
      • Harrison, New York, États-Unis, 10604
        • Recrutement
        • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
        • Contact:
          • Yelena Janjigian, MD
          • Numéro de téléphone: 646-888-4186
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • Contact:
          • Yelena Y Janjigian, MD
          • Numéro de téléphone: 646-888-4186
      • Uniondale, New York, États-Unis, 11553
        • Recrutement
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • Contact:
          • Yelena Janjigian, MD
          • Numéro de téléphone: 646-888-4186
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • Actif, ne recrute pas
        • University of Pennsylvania (Data Collection Only)
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • MD Anderson Cancer Center (Data Collection Only)
        • Contact:
          • Jennifer Li, MD
          • Numéro de téléphone: 855-760-5921

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age 18 years or older at time of signing informed consent.
  • ECOG performance status 0-1.
  • HER2+ esophageal, GEJ, or gastric adenocarcinoma biopsy or resection specimen as defined by local HER2 IHC3+ or IHC 2+/FISH>2.0 expression.
  • Complete surgical resection of the primary tumor must be achievable
  • Demonstrate adequate organ function as defined in Table 1.

Table 1 - Organ Function Requirements for Eligibility Hematological

  • Absolute neutrophil count (ANC): ≥1,500 /mcL

  • Platelets: ≥100,000 / mcL

  • Hemoglobin: ≥8 g/dL Renal

  • Creatinine clearance: ≥ 50 mL/minute Hepatic

  • Serum total bilirubin: ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN. Except patients with Gilbert's disease (≤3x ULN)

  • AST and ALT: ≤ 2.5 X ULN

  • Albumin: >3 mg/dL Coagulation

  • International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT): <1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

  • Male participants: A male participant must agree to use contraception as detailed in Section 15.3 of this protocol during the treatment period and for at least 230 days (5 terminal half-lives of trastuzumab [140] plus an additional 90 days [spermatogenesis cycle]) after the last dose of study treatment and refrain from donating sperm during this period.

  • Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP) as defined in section 15.3 OR
    2. A WOCBP who agrees to follow the contraceptive guidance in section 15.3 during the treatment period and for at least 170 days (140 days plus an additional 30 days [menstruation cycle]) after the last dose of study treatment.

Exclusion Criteria:

  • Presence of metastatic or recurrent disease.

  • Has received prior treatment for esophagogastric cancer

  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.

  • Has received prior therapy with an anti-HER2 agent

  • Left ventricular ejection fraction <50% within 1 month of screening by MUGA or echocardiogram. Patients with an ejection fraction 45-49% may be permissible in the absence of any cardiac symptoms, if cleared by a cardiologist, and per the investigator's discresion.

  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

  • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast premedication) may be enrolled.

  • The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

  • Has a known history of active TB (Bacillus tuberculosis)

  • Hypersensitivity to pembrolizumab or any of its excipients

  • Has been diagnosed or treated for another malignancy in the past 3 years (not including non-melanoma skin cancer)

  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

  • Has known history of, or any evidence of active, non-infectious pneumonitis.

  • Has an active infection requiring systemic therapy.

  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.

  • A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  • Has had an allogeneic tissue or solid organ transplant

  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease; systemic lupus erythematosus; Wegener syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis, hypophysitis, uveitis) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

    • Subjects with vitiligo or alopecia
    • Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment.
    • Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  • Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).

  • Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

  • Is unwilling to give written informed consent, unwilling to participate, or unable to comply with the protocol for the duration of the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Esophagogastric Cancer

Participants will have a diagnosis of resectable HER2+ (IHC 3+ or IHC 2+/FISH ratio >2.0) esophageal, GEJ or gastric cancer.

Pembrolizumab will be administered on an every 3-week dosing schedule

Trastuzumab will be administered on an every 3-week dosing schedule

Oxaliplatin every 3 weeks, +/-7 days

Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks

5-Fluorouracil administered as a 24 hour IV continuous infusion once every 2 weeks

Docetaxel administered intravenously once every 2 weeks.

will be collected (optionally)

will be collected (optionally)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Event-free survival (EFS)
Délai: 2 years

EFS is defined as the time from start of treatment to time of disease progression, recurrence, or death, whichever occurs first.

2 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 février 2024

Achèvement primaire (Estimé)

30 novembre 2027

Achèvement de l'étude (Estimé)

30 novembre 2027

Dates d'inscription aux études

Première soumission

3 novembre 2023

Première soumission répondant aux critères de contrôle qualité

3 novembre 2023

Première publication (Réel)

8 novembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner